Cellules souches

Brontictuzumab (OMP 52M5) is an anti-Notch1 monoclonal antibody with antitumor activity that inhibits tumor cell proliferation.

Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.

SAR407899 hydrochloride is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and

Galunisertib (LY2157299) is a selective TGF-β receptor type I (TGF-βRI) inhibitor. Galunisertib has antitumor activity. Cost-effective and quality-assured.

JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].

Nefopam hydrochloride (Nefopam HCl) is the hydrochloride salt form of nefopam, a centrally-acting, non-opioid benzoxazocine with analgesic activity.

STAT3HiBiT degrader 1 is a potent degrader of STAT3HiBiT, exhibiting a DC50 of less than 0.05 μM in A549 cells.

Casein kinase 1δ-IN-5 is a potent and selective CK-1δ inhibitor, exhibiting an IC50 of 47 nM, and demonstrates neuroprotective and anti-inflammatory effects in

JK184 is a potent Hedgehog (Hh) pathway inhibitor.

TINK-IN-1 is a selective and potent TNIK inhibitor (IC50: 8 nM).TINK-IN-1 inhibits colorectal cancer cell viability and can be used to study mental retardation.

Fresolimumab (GC1008) is a human monoclonal antibody targeting active TGFβ1, TGFβ2, TGFβ3, studied for cancer and focal segmental glomerulosclerosis.

TAK-441: oral Hedgehog signal blocker, potent anticancer, IC50=4.4 nM, reduces Gli1 mRNA & tumor growth.

JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important

β-catenin/CBP-IN-1 is a potent and selective inhibitor of CBP/β-catenin

Chroman 1 is a potent inhibitor of ROCK1 (IC50 = 52 pM) and ROCK2 (IC50 = 1 pM).

Pyrvinium pamoate (Pyrvinium embonate) is an old anthelminthic medicine for the treatment of enterobiasis , which re-attracts attention as an anti-cancer drug

β-catenin-IN-2 is a potent inhibitor of β-catenin that can be used in colorectal cancer research.

KY02111 facilitates differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling, maybe affect downstream of GSK3β and APC.

MRT-81 blocks Smo receptors in Shh-light2 cells at 41 nM IC50, showing strong hedgehog pathway inhibition, useful in cancer research.

CK1δ-IN-6: potent, selective CK-1δ inhibitor, IC50 23 nM, neuroprotective, anti-inflammatory, for neurodegenerative research.

2-NP is a STAT1 enhancer.

Avagacestat (BMS-708163) (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM,

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Simian OC/BGP. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Simian OC/BGP. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Simian OC/BGP, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Simian OC/BGP in the samples is then determined by comparing the OD of the samples to the standard curve.

AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor.

GSK-3 inhibitor 1 is a GSK-3 inhibitor.

ROCK inhibitor-2 is a selective dual inhibitor of ROCK1 and ROCK2 (IC50s of 17 nM and 2 nM, respectively).

EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively.

GSK-3 inhibitor 3 is a selective, orally active, brain-permeable GSK-3 inhibitor that inhibits GSK-3α and GSK-3β with IC50s of 0.35 nM and 0.25 nM, respectively

MRT-92 is an antagonist of Smoothened (Smo) with anti-cancer activity, featuring a binding affinity (Ki) of 0.7 nM. It inhibits the Hedgehog signaling pathway by obstructing the overlapping binding sites within the transmembrane domain of the Smoothened receptor and suppresses the proliferation of cerebellar granule cells in rodents (IC50=0.4 nM). MRT-92 is utilized for research into cerebellar gliomas.

YAP-TEAD-IN-3 inhibitor YAP/TAZ-TEAD interactions Avi-human TEAD (4217-434) YAP-TEAD-IN-3 inhibits YAP reporter gene expression and NCI-H2052 cell proliferation

GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).

BMS-863233 HCl is an ATP-competitive Cdc7 inhibitor (IC50: 3.4 nM) that is potent and selective.BMS-863233 HCl inhibited CK2 and PIM1 with IC50 values of 215

VT104 is a potent and orally active YAP/TAZ inhibitor for cancer research.Cost-effective and quality-assured.

RKI1313 (RKI-1313) was a selective inhibitor for ROCK-dependent signaling, cytoskeletal changes, anchorage-independent colony formation, migration, and invasion

VT107 is a potent pan-TEAD autopalmitoylation inhibitor. VT-107 can be used in cancer therapy research.Cost-effective and quality-assured.

Pentabromophenol (NSC-5717) suppressed TGF-β response by accelerating the turnover rate of TGF-β receptors.

dCK1α-2 is an orally effective CK1α molecular glue (Molecular Glue) degrader that targets p53 pathway-related targets. It demonstrates antitumor efficacy in mouse models by enhancing the expression of p53-related genes.

GSK-3β inhibitor 11 (compound 21) is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β) with an inhibitory concentration (IC50) of 10.02 μM.

BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705.

JLK6 was a gamma-secretase inhibitor that does not interfere with Notch signalling

Linavonkibart (SRK181) is a humanized antibody targeting TGFβ1 that blocks the release of TGF-β1 protein by specifically binding latent TGF-β1.

XMU-MP-1 is an inhibitor of the pro-apoptotic, sterile 20-like kinases MST1 and 2.

STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.

SSTC3 is a casein kinase 1α (CK1α) activator with potential antitumor activity that inhibits WNT signaling.

GSK269962A (GSK269962A HCl) is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

Akt/ROCK-IN-1 (B12) is a dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively.

JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.

CWP232228 is a selective Wnt/β-catenin pathway inhibitor targeting β-catenin/TCF binding, halting breast/liver CSC growth and metastasis safely.

GSK-3 InhibitorXIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.

SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway.